Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance
- 17 July 2009
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 23 (11), 1359-1366
- https://doi.org/10.1097/qad.0b013e32832c4152
Abstract
To determine whether antiretroviral regimens with good central nervous system (CNS) penetration control HIV in cerebrospinal fluid (CSF) and improve cognition. Multisite longitudinal observational study. Research clinics. One hundred and one individuals with advanced HIV beginning or changing a new potent antiretroviral regimen were enrolled in the study. Data for 79 participants were analyzed. Participants underwent structured history and neurological examination, venipuncture, lumbar puncture, and neuropsychological tests at entry, 24, and 52 weeks. Antiretroviral regimens were categorized as CNS penetration effectiveness (CPE) rank of at least 2 or less than 2. Generalized estimating equations were used to examine associations over the course of the study. Concentration of HIV RNA in CSF and blood and neuropsychological test scores (NPZ4 and NPZ8). Odds of suppression of CSF HIV RNA were higher when CPE rank was at least 2 than when it was less than 2. Odds of suppression of plasma HIV RNA were not associated with CPE rank. Among participants with impaired neuropsychological performance at entry, those prescribed regimens with a CPE rank of at least 2 or more antiretrovirals had lower composite NPZ4 scores over the course of the study. Antiretroviral regimens with good CNS penetration, as assessed by CPE rank, are more effective in controlling CSF (and presumably CNS) viral replication than regimens with poorer penetration. In this study, antiretrovirals with good CNS penetration were associated with poorer neurocognitive performance. A larger controlled trial is required before any conclusions regarding the influence of specific antiretrovirals on neurocognitive performance should be made.Keywords
This publication has 20 references indexed in Scilit:
- Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disordersAnnals of Neurology, 2004
- Changing incidence of central nervous system diseases in the EuroSIDA cohortAnnals of Neurology, 2004
- Changes in CSF and plasma HIV-1 RNA and cognition after starting potent antiretroviral therapyNeurology, 2003
- Factors influencing virological response to antiretroviral drugs in cerebrospinal fluid of advanced HIV-1-infected patientsAIDS, 2002
- Progression to Neuropsychological Impairment in Human Immunodeficiency Virus Infection Predicted by Elevated Cerebrospinal Fluid Levels of Human Immunodeficiency Virus RNAArchives of Neurology, 2002
- Determining the extent of cognitive change after coronary surgery: a review of statistical proceduresThe Annals of Thoracic Surgery, 2002
- Relationship between human immunodeficiency virus—associated dementia and viral load in cerebrospinal fluid and brainAnnals of Neurology, 1997
- Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndromeAnnals of Neurology, 1997
- Levels of human immunodeficiency virus type 1 RNA in cerebrospinal fluid correlate with AIDS dementia stage.The Journal of Infectious Diseases, 1997
- Statistics notes: Calculating correlation coefficients with repeated observations: Part 2--correlation between subjectsBMJ, 1995